Omalizumab (Xolair) for Food Allergies in Children
The short answer
Omalizumab (brand name Xolair) received FDA approval in 2024 as the first biologic therapy for food allergies in children ages 1 and older. It works by blocking IgE antibodies, which are responsible for allergic reactions, thereby raising the threshold of allergen needed to trigger a reaction. In clinical trials, after 16-20 weeks of treatment, 67% of participants could tolerate the equivalent of 2-3 peanuts without a reaction, compared to 7% on placebo. Omalizumab does not cure food allergies but provides a significant safety net against accidental exposures. It is given as an injection every 2-4 weeks.
Parents everywhere have the same worry. You are doing the right thing by looking into it.
By Age
What to expect by age
12-24 months
Food allergies are commonly diagnosed in this age range, with peanut, milk, egg, and tree nut allergies being most prevalent. Omalizumab is FDA-approved for children age 1 and older with IgE-mediated food allergies. For very young children, the decision to use omalizumab should weigh the severity of the allergy, the risk of accidental exposure, and the burden of injections. Some families may prefer to first try oral immunotherapy (OIT) or baked-milk/baked-egg laddering for milk and egg allergies. Discuss all options with a board-certified pediatric allergist.
2-5 years
This age range may benefit most from omalizumab because accidental exposures become more common as children enter daycare and preschool settings where food exposure is harder to control. Omalizumab is particularly valuable for children with multiple food allergies, as OIT typically addresses only one allergen at a time. The medication can be used alongside OIT to improve its safety and effectiveness. Side effects include injection site reactions and, rarely, anaphylaxis to the medication itself (which is why the first doses are given in a medical setting with monitoring).
5 years and older
School-age children face frequent food allergy challenges in school cafeterias, birthday parties, and social settings. Omalizumab reduces but does not eliminate the risk of allergic reactions, so strict allergen avoidance and carrying epinephrine must continue. The medication requires ongoing injections every 2-4 weeks, and its effects wear off if discontinued. Cost can be significant (list price around $2,500/month), though most insurance plans and the manufacturer's patient assistance program can reduce out-of-pocket costs. Long-term safety data are still being collected.
What Should You Do?
When to take action
- Your child's food allergies are well-managed with avoidance, they carry epinephrine, and they have not had recent accidental exposures.
- Your child is undergoing successful OIT and does not need additional treatment.
- Your child has outgrown a food allergy, as confirmed by supervised oral food challenge.
- Your child has severe or multiple food allergies and you want to discuss omalizumab as a treatment option.
- Your child has frequent accidental exposures despite best avoidance efforts.
- You want to understand the differences between omalizumab, OIT, and other emerging food allergy treatments.
- Your child's food allergies are significantly impacting quality of life and you want to explore all options.
- Your child is having an allergic reaction (hives, vomiting, difficulty breathing, swelling) - use epinephrine and call 911.
- Your child had an anaphylactic reaction to an omalizumab injection - seek emergency care.
- Your child ingested a known allergen and is showing any symptoms of an allergic reaction.
Sources
Related Resources
Trust your instincts. If something feels wrong, reach out to your pediatrician.
Worrying about your baby means you care. That is a good thing.
Related Medical Concerns
Oral Immunotherapy (OIT) for Food Allergies in Toddlers
Oral immunotherapy (OIT) is a treatment that gradually introduces small, increasing doses of a food allergen to raise the threshold of tolerance and reduce the risk of severe reactions from accidental exposure. Palforzia (peanut allergen powder) is FDA-approved for peanut allergy in children 4-17 years old, but many allergists offer OIT off-label for younger children and other allergens. OIT does not cure food allergies but can provide significant protection. Success rates for desensitization range from 60-85%, though the maintenance dose must be continued indefinitely. OIT carries risks, including allergic reactions during treatment, and should only be conducted under the supervision of an experienced allergist.
Baby Hives (Urticaria)
Hives are raised, red, itchy welts that can appear suddenly on your baby's skin. They are most often caused by a viral infection or an allergic reaction to food, medication, or an insect bite. While they can look alarming, hives are usually harmless and resolve on their own, though any breathing difficulty needs immediate emergency care.
My Baby Got a Rash After Antibiotics
A rash during or after antibiotics is very common in babies and children, occurring in up to 10% of those taking amoxicillin. Most antibiotic rashes are non-allergic reactions that appear as flat, pink, widespread spots and are not dangerous. However, it is important to distinguish this from a true allergic reaction involving hives, so contact your pediatrician to help determine which type of rash your baby has.
My Baby's Head Shape Looks Abnormal
Many babies develop temporary head shape irregularities that are completely normal. A cone-shaped head from vaginal delivery reshapes within days. Mild positional flattening (plagiocephaly) from sleeping on the back is very common and usually improves with repositioning and tummy time. However, head shape changes involving ridges, a persistently bulging fontanelle, or rapid head growth changes should be evaluated to rule out craniosynostosis.
Achondroplasia (Dwarfism) in Babies
Achondroplasia is the most common form of short-limbed dwarfism, affecting about 1 in 15,000 to 40,000 births. It is caused by a mutation in the FGFR3 gene and is usually apparent at birth with characteristic features including short limbs, a larger head, and a prominent forehead. Intelligence is normal. With monitoring for specific complications and supportive care, children with achondroplasia lead full, active, and independent lives.
Adenoid Hypertrophy and Breathing
Adenoids are lymphoid tissue located behind the nose that help fight infection in young children. When adenoids become enlarged (adenoid hypertrophy), they can block the nasal airway, causing chronic mouth breathing, snoring, nasal speech, and sleep-disordered breathing. Enlarged adenoids are most common between ages 2-7 and are a leading cause of obstructive sleep apnea in young children. Treatment ranges from watchful waiting and nasal steroids to surgical removal (adenoidectomy) if breathing or sleep is significantly affected.